Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy ...

Everybody loves a villain and when it comes to 1923, no one is better at it than French-American actor Sebastian Roché. In ...

MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide ...

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Despite the trial not meeting its primary endpoint, the high dose was well tolerated, with a safety profile comparable to the approved 600 mg dose and no new safety signals observed. These findings ...

FARMINGDALE - James Barry Roche ("Barry," “Hugsy Bear”), 91, of Farmingdale, passed away peacefully at home on March 24, 2025 ...

Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

Shareholders approved all proposals of the Board of Directors Severin Schwan was re-elected as Chairman of the Board of ...

The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy ...